Joint Corp (JYNT) Director Ronald V. Davella Sells 3,000 Shares of Stock

Joint Corp (NASDAQ:JYNT) Director Ronald V. Davella sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $7.62, for a total transaction of $22,860.00. Following the completion of the sale, the director now directly owns 15,797 shares of the company’s stock, valued at $120,373.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Joint stock traded up $0.14 on Friday, reaching $7.53. The stock had a trading volume of 4,383 shares, compared to its average volume of 27,145. The company has a current ratio of 1.36, a quick ratio of 1.36 and a debt-to-equity ratio of 0.75. Joint Corp has a fifty-two week low of $4.67 and a fifty-two week high of $9.64. The stock has a market capitalization of $105.61 million, a price-to-earnings ratio of -30.12 and a beta of 1.02.

Joint (NASDAQ:JYNT) last issued its quarterly earnings data on Thursday, November 8th. The company reported $0.01 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.02 by ($0.01). Joint had a negative return on equity of 21.00% and a negative net margin of 2.68%. The firm had revenue of $8.06 million during the quarter, compared to analyst estimates of $7.98 million. As a group, research analysts predict that Joint Corp will post 0.06 earnings per share for the current year.

JYNT has been the subject of a number of analyst reports. Roth Capital restated a “buy” rating on shares of Joint in a research note on Friday, August 10th. Zacks Investment Research cut shares of Joint from a “buy” rating to a “hold” rating in a research note on Thursday, October 11th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $10.58.

Institutional investors have recently modified their holdings of the company. Granahan Investment Management Inc. MA acquired a new stake in shares of Joint in the second quarter worth $1,325,000. Tower Research Capital LLC TRC raised its stake in Joint by 20,991.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 12,444 shares of the company’s stock valued at $102,000 after purchasing an additional 12,385 shares during the last quarter. Bandera Partners LLC acquired a new position in Joint during the 2nd quarter valued at $10,669,000. Acadian Asset Management LLC raised its stake in Joint by 25.1% during the 3rd quarter. Acadian Asset Management LLC now owns 177,843 shares of the company’s stock valued at $1,522,000 after purchasing an additional 35,716 shares during the last quarter. Finally, Redmond Asset Management LLC acquired a new position in Joint during the 2nd quarter valued at $408,000. Institutional investors and hedge funds own 51.43% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.dispatchtribunal.com/2018/12/07/joint-corp-jynt-director-ronald-v-davella-sells-3000-shares-of-stock.html.

About Joint

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of August 9, 2018, the company operated approximately 400 clinics. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.

See Also: What do investors mean by earnings per share?

Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply